Search

Your search keyword '"Sasaki, Hikaru"' showing total 60 results

Search Constraints

Start Over You searched for: Author "Sasaki, Hikaru" Remove constraint Author: "Sasaki, Hikaru" Topic brain neoplasms Remove constraint Topic: brain neoplasms
60 results on '"Sasaki, Hikaru"'

Search Results

1. Development of microsurgical forceps equipped with haptic technology for in situ differentiation of brain tumors during microsurgery.

2. Status of alternative angiogenic pathways in glioblastoma resected under and after bevacizumab treatment.

3. Oligodendroglioma, IDH-mutant and 1p/19q-codeleted-prognostic factors, standard of care and chemotherapy, and future perspectives with neoadjuvant strategy.

4. An exploratory prospective phase II study of preoperative neoadjuvant bevacizumab and temozolomide for newly diagnosed glioblastoma.

5. Clinical, histopathological and molecular risk factors for recurrence of pilocytic astrocytomas: brainstem/spinal location, nestin expression and gain of 7q and 19 are associated with early tumor recurrence.

6. The role of optimal cut-off diagnosis in 11C-methionine PET for differentiation of intracranial brain tumor from non-neoplastic lesions before treatment.

7. A common deletion at BAK1 reduces enhancer activity and confers risk of intracranial germ cell tumors.

8. [Glioblastoma That Does Not Improve with Standard Treatment: Standard and Personalized Treatment Making The Most of Limited Modalities].

9. The oligodendroglial histological features are not independently predictive of patient prognosis in lower-grade gliomas.

10. Determining the extent of tumor resection at surgical planning with 18 F-fluciclovine PET/CT in patients with suspected glioma: multicenter phase III trials.

11. Histopathological investigation of the 1p/19q-codeleted gliomas resected following alkylating agent chemotherapy.

12. Myoinositol to Total Choline Ratio in Glioblastomas as a Potential Prognostic Factor in Preoperative Magnetic Resonance Spectroscopy.

13. Molecular investigation of brain tumors progressing during pregnancy or postpartum period: the association between tumor type, their receptors, and the timing of presentation.

14. Association of preoperative seizures with tumor metabolites quantified by magnetic resonance spectroscopy in gliomas.

15. Anti-EGFR VHH-armed death receptor ligand-engineered allogeneic stem cells have therapeutic efficacy in diverse brain metastatic breast cancers.

16. TERT promoter mutation confers favorable prognosis regardless of 1p/19q status in adult diffuse gliomas with IDH1/2 mutations.

17. The Correlation of Fluorescence of Protoporphyrinogen IX and Status of Isocitrate Dehydrogenase in Gliomas.

18. Magnetic resonance imaging texture analyses in lower-grade gliomas with a commercially available software: correlation of apparent diffusion coefficient and T2 skewness with 1p/19q codeletion.

19. Genetic analysis in patients with newly diagnosed glioblastomas treated with interferon-beta plus temozolomide in comparison with temozolomide alone.

20. Clinical and histopathological analyses of VEGF receptors peptide vaccine in patients with primary glioblastoma - a case series.

21. Immunohistochemistry for O 6 -methylguanin-DNA methyltransferase in glioblastomas defined by WHO2016: Correlation with promoter methylation status and patients' progression-free survival with the cut-off value determined by ROC analysis.

22. Tumor immune microenvironment is associated with the growth of intracranial germinomas.

23. Predictive markers for MGMT promoter methylation in glioblastomas.

24. c-Met Expression Is a Useful Marker for Prognosis Prediction in IDH-Mutant Lower-Grade Gliomas and IDH-Wildtype Glioblastomas.

25. Imaging scoring systems for preoperative molecular diagnoses of lower-grade gliomas.

26. Persistent restoration to the immunosupportive tumor microenvironment in glioblastoma by bevacizumab.

27. Difference in Immunosuppressive Cells Between Peritumoral Area and Tumor Core in Glioblastoma.

28. Association between programmed cell death ligand-1 expression and extracranial metastasis in intracranial solitary fibrous tumor/hemangiopericytoma.

29. JCOG0911 INTEGRA study: a randomized screening phase II trial of interferonβ plus temozolomide in comparison with temozolomide alone for newly diagnosed glioblastoma.

30. Histopathological vascular investigation of the peritumoral brain zone of glioblastomas.

31. Comprehensive genetic characterization of rosette-forming glioneuronal tumors: independent component analysis by tissue microdissection.

32. Treatment Recommendations for Adult Patients with Diffuse Gliomas of Grades II and III According to the New WHO Classification in 2016.

33. Unusual Magnetic Resonance Imaging Findings of a Glioblastoma Arising During Treatment with Lenvatinib for Thyroid Cancer.

34. Clinical and Molecular Prognostic Factors for Long-Term Survival of Patients with Glioblastomas in Single-Institutional Consecutive Cohort.

35. A case of glioblastoma resected immediately after administering bevacizumab: consideration on histopathological findings and safety of surgery.

36. Bevacizumab for malignant gliomas: current indications, mechanisms of action and resistance, and markers of response.

37. Molecular-genetic and clinicopathological prognostic factors in patients with gliomas showing total 1p19q loss: gain of chromosome 19p and histological grade III negatively correlate with patient's prognosis.

38. A case of papillary tumor of the pineal region with a long clinical history: molecular characterization and therapeutic consideration with review of the literature.

39. Histopathological investigation of glioblastomas resected under bevacizumab treatment.

41. PCR-Based Simple Subgrouping Is Validated for Classification of Gliomas and Defines Negative Prognostic Copy Number Aberrations in IDH Mutant Gliomas.

42. Upfront chemotherapy and subsequent resection for molecularly defined gliomas.

43. Molecular-genetic and clinical characteristics of gliomas with astrocytic appearance and total 1p19q loss in a single institutional consecutive cohort.

44. [Neoadjuvant therapy in the treatment of brain tumours].

45. Case of radiologically multicentric but genetically identical multiple glioblastomas.

46. Surgical navigation-assisted endoscopic biopsy is feasible for safe and reliable diagnosis of unresectable solid brain tumors.

47. Immunohistochemical and molecular genetics study of a granular cell astrocytoma: a case report of malignant transformation to a glioblastoma.

48. Randomized trial of chemoradiotherapy and adjuvant chemotherapy with nimustine (ACNU) versus nimustine plus procarbazine for newly diagnosed anaplastic astrocytoma and glioblastoma (JCOG0305).

49. A glioblastoma arising from the attached region where a meningioma had been totally removed.

50. Molecular characteristics of pediatric non-ependymal, non‑pilocytic gliomas associated with resistance to temozolomide.

Catalog

Books, media, physical & digital resources